Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2012
10/04/2012WO2012133246A1 Carotenoid-containing composition and method for producing same
10/04/2012WO2012133121A1 Long-lasting controlled-release liposome composition and method for producing same
10/04/2012WO2012133005A1 Fat-reducing agent
10/04/2012WO2012132747A1 Liquid composition for oral cavity and method for stable addition of components to composition
10/04/2012WO2012132251A1 Porous carbon material, adsorbent, orally administrable adsorbent, adsorbent for medical use, filler for blood purification column, adsorbent for water purification, cleansing agent, carrier, agent for extended release of drugs, cell culture scaffold material, mask, carbon/polymer composite, adsorptive sheet, and functional food
10/04/2012WO2012132141A1 Composition for delivering drug into cell and method therefor
10/04/2012WO2012131722A1 Controlled release composition of betahistine
10/04/2012WO2012131678A1 Sustained-release injectable formulation
10/04/2012WO2012131527A1 Antibody-drug conjugates
10/04/2012WO2012131476A1 Composition and method for controlling release of active ingredient
10/04/2012WO2012131348A1 Salicylic acid topical formulation
10/04/2012WO2012131347A1 Usnic acid topical formulation
10/04/2012WO2012131306A1 Pharmaceutical preparation
10/04/2012WO2012131106A1 Biodegradable compositions suitable for controlled release
10/04/2012WO2012131104A2 Biodegradable compositions suitable for controlled release
10/04/2012WO2012131095A1 Compositions comprising a filler product and at least one bioresorbable and biodegradable silica-based material
10/04/2012WO2012131018A1 Nanoparticles loaded with chemotherapeutic antitumoral drug
10/04/2012WO2012130941A2 Perfluorinated compounds for the non-viral transfer of nucleic acids
10/04/2012WO2012130866A1 Novel glucagon analogues
10/04/2012WO2012130819A1 Otamixaban formulations with improved stability
10/04/2012WO2012130336A1 Delivery of large molecular weight biologically active substances
10/04/2012WO2012130193A1 Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
10/04/2012WO2012130116A1 Compound preparation treating alzheimer's disease and preparation method thereof
10/04/2012WO2012130015A1 Site-directed mono-substituted pegylated exendin analog and preparation method therefor
10/04/2012WO2012129767A1 Pharmaceutical composition comprising cation modified agarose hydrogel and nucleic acid, preparation method and use thereof
10/04/2012WO2012129759A1 Oral dosage formulations containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders
10/04/2012WO2012107416A3 Improved immunotherapy
10/04/2012WO2012094541A3 Acoustically responsive particles with decreased cavitation threshold
10/04/2012WO2012088094A3 Il-1 binding proteins
10/04/2012WO2012066537A3 Compositions for transdermal delivery of active agents
10/04/2012WO2012036585A8 Pharmaceutical composition with antimicrobial activity for parenteral administration and process for preparing same
10/04/2012WO2012006169A3 Compositions and methods for enhancement of nucleic acid delivery
10/04/2012WO2011143524A3 Functional, cross-linked nanostructures for tandem optical imaging and therapy
10/04/2012WO2011090694A8 Orally administrable film dosage forms containing ondansetron
10/04/2012US20120252906 Bioavailability Enhancement Delivery Composition
10/04/2012US20120252905 Drug delivery from rapid gelling polymer composition
10/04/2012US20120252862 Dissolvable Film Strip Comprising Natural Components
10/04/2012US20120252861 Medical Compositions for Intravesical Treatment of Bladder Cancer
10/04/2012US20120252832 Abuse-resistant controlled-release opioid dosage form
10/04/2012US20120252795 Oral lysophilisates containing pvp/va
10/04/2012US20120252771 Implants and methods for treating inflammation-mediated conditions of the eye
10/04/2012US20120252732 Albumin fusion proteins
10/04/2012US20120252097 Therapeutic Agents Comprising Pro-Apoptotic Proteins
10/04/2012US20120251622 Cellulose gum and polyol troche
10/04/2012US20120251620 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
10/04/2012US20120251600 Skin compositions and methods of use thereof
10/04/2012US20120251594 Delivery of Submicrometer and Nanometer Aerosols to the Lungs Using Hygroscopic Excipients or Dual Stream Nasal Delivery
10/04/2012US20120251593 Silk fibroin-decorin scaffolds
10/04/2012US20120251588 Coating Composition, Solid Preparation Coated Therewith, and Method for Preparing Solid Preparation
10/04/2012US20120251582 Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
10/04/2012US20120251559 Treatment of B-Cell Cancers With Anti-CD70 Antibody-Drug Conjugates
10/04/2012US20120251532 Anti-alpha v beta 6 antibodies
10/04/2012US20120251521 Technical field and industrial applicability of the invention
10/04/2012US20120251484 Cold prepared gel and method for making same
10/04/2012US20120251460 Use of vanillin derivatives as a preservative, preservation method, compounds, and composition
10/04/2012US20120251445 Peptides whose uptake by cells is controllable
10/04/2012US20120251441 Adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of clinical manifestations associated with diseases like cachexia and correction of adverse effects of drugs such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier specially selected and other substances with antineoplastic action and/or other treatments
10/04/2012CA2831566A1 Menthol liquids composition
10/04/2012CA2831562A1 Process for manufacturing conjugates of improved homogeneity
10/04/2012CA2831486A1 Pharmaceutical preparation
10/04/2012CA2831471A1 Biodegradable compositions suitable for controlled release
10/04/2012CA2831469A1 Biodegradable compositions suitable for controlled release
10/04/2012CA2831467A1 Preparation of maytansinoid antibody conjugates by a one-step process
10/04/2012CA2831426A1 Methods for increasing efficacy of folr1 cancer therapy
10/04/2012CA2831392A1 Conjugated lipomers and uses thereof
10/04/2012CA2831336A1 T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
10/04/2012CA2831218A1 Controlled release pharmaceutical dosage forms
10/04/2012CA2831111A1 Cd37-binding molecules and immunoconjugates thereof
10/04/2012CA2830974A1 Novel glucagon analogues
10/04/2012CA2830962A1 Otamixaban formulations with improved stability
10/04/2012CA2830948A1 Osmotic mediated release synthetic nanocarriers
10/04/2012CA2830664A1 Pegylated human hdl particle and process for production thereof
10/04/2012CA2830654A1 Compositions comprising a filler product and at least one bioresorbable and biodegradable silica-based material
10/04/2012CA2830375A1 Methods and compositions for targeting adipose cells in mammals
10/04/2012CA2830338A1 Antibody-drug conjugates
10/04/2012CA2830324A1 Perfluorinated compounds for non-viral transfer of nucleic acids
10/04/2012CA2829791A1 Sustained-release injectable formulation
10/04/2012CA2829241A1 Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics
10/04/2012CA2829122A1 Site-directed mono-substituted pegylated exendin analog and preparation method therefor
10/04/2012CA2822177A1 Nanoparticles loaded with chemotherapeutic antitumoral drug
10/03/2012EP2505590A1 Method for making a hydrophobic cluster compound soluble or dispersible in water
10/03/2012EP2505211A1 Molecules for targeting compounds to various selected organs or tissues
10/03/2012EP2505210A1 Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanionic polypeptide for the treatment of aids
10/03/2012EP2505207A2 Modified exendins and uses thereof
10/03/2012EP2505194A2 Nicotine-containing patch preparation
10/03/2012EP2505192A1 Use of carriers as preservatives and pharmaceutical composition containing same
10/03/2012EP2505189A1 Stabilizing alkylglycoside compositions and method thereof
10/03/2012EP2504370A1 Acrylic or methacrylic polymer including alpha-tocopherol grafts
10/03/2012EP2504034A1 Topical ibuprofen formulations
10/03/2012EP2504033A1 Film-like pharmaceutical dosage forms
10/03/2012EP2504027A1 Acceleration of wound healing by a tissue inhibitor of metalloproteinases (timp) linked to glycosylphosphatidylinositol (gpi)-anchors
10/03/2012EP2504022A1 Brain tumor targeting peptides and methods
10/03/2012EP2504021A1 Polypeptide conjugate
10/03/2012EP2504020A1 Formulations of daptomycin
10/03/2012EP2504019A2 Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
10/03/2012EP2504012A2 Use of an oleo gel containing triterpene for healing wounds
10/03/2012EP2503992A1 Formulations of bisphosphonates and vitamin d suitable for intermittent intramuscular and subcutaneous administration
10/03/2012EP2503989A2 Topical foam composition
10/03/2012EP2503988A2 Topical foam composition
10/03/2012EP2428205B1 Modified release formulations containing drug-ion exchange resin complexes
1 ... 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 ... 1712